行情

TTPH

TTPH

Tetraphase制药
NASDAQ

实时行情|Nasdaq Last Sale

0.3772
+0.0012
+0.32%
盘前: 0.3665 -0.0107 -2.84% 08:14 09/16 EDT
开盘
0.4000
昨收
0.3760
最高
0.4198
最低
0.3421
成交量
700
成交额
--
52周最高
3.205
52周最低
0.2250
市值
2,048.82万
市盈率(TTM)
-0.2426
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TTPH 新闻

  • What Kind Of Shareholder Owns Most Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock?
  • Simply Wall St..3天前
  • Benzinga's Top Upgrades, Downgrades For September 3, 2019
  • Benzinga.09/03 13:42
  • H.C. Wainwright Downgrades Tetraphase Pharmaceutical to Neutral
  • Benzinga.09/03 12:10
  • Edited Transcript of TTPH earnings conference call or presentation 8-Aug-19 8:30pm GMT
  • Thomson Reuters StreetEvents.09/02 21:33

更多

所属板块

制药
-0.54%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

TTPH 简况

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
展开

Webull提供Tetraphase Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。